AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Fletcher dodges product recall in upbeat end to August for NZX 50
Markets

Fletcher dodges product recall in upbeat end to August for NZX 50

The S&P/NZX 50 Index rose 97.07 points, or 0.8%, to 12,447.68.

Paul McBeth 30 Aug 2024
Fletcher Building expects $168m hit from leaky pipes response
Markets

Fletcher Building expects $168m hit from leaky pipes response

Fletcher Building subsidiary Iplex Australia to cover 80% of repair costs.

John Anthony 30 Aug 2024
Ritchies posts $17m annual net loss
Markets

Ritchies posts $17m annual net loss

The bus operator's net loss widened from $8m to $17m in the year to March 31.

John Anthony 30 Aug 2024
Fletcher shares in trading halt as leaky pipes announcement looms
Markets

Fletcher shares in trading halt as leaky pipes announcement looms

Fletcher Building is awaiting an announcement from the Government of Western Australia.

John Anthony 30 Aug 2024